In order to determine the role of glutathione reductase (GR) in protection against Alphtalocyanine tetrasulfonate-sensitized human erythrocyte photolysis, we have studied the effects of antitumour alkylating agents that inactivate GR, on photohemolysis rate. The rates of inactivation of reduced GR decreased in order BCNU > pharanox (N-p-[bis-(2-chloroethyl)-amino]-phenylacetic acid N-oxide) > phenalol (N-p-[bis-(2-chloroethyl)-amino]-phenylacetyl-L- phenylalanine) > o-F- and p-F-lophenal (o- and p-isomers of N-p-[bis-(2-chloroethyl)-amino]-phenylacetyl-D,L-fluorophenylalanine) > D,L-melphalan. As supposed, erythrocyte photolysis was accelerated by BCNU and pharanox, however, it was slowed down by phenylalanine mustards. The latter effect was explained by singlet oxygen quenching and/or photooxidation reactions of these compounds. This points out to a possibility of certain phenylalanine derivatives to neutralize the side-effects of photodynamic therapy.

01 Mar 1998·Pathology & Oncology ResearchQ4 · MEDICINE

Embryotoxicity and teratogenicity of some derivatives of chloroethylaminophenylacetic acid

Q4 · MEDICINE

Article

Author: V. Zalgeviciene ; G. Sinkeviciute ; J. Didziapetriene ; G. Grazeliene ; J. Zukiene

Embryotoxic and teratogenic properties of Lophenal, Phenalon, Pharanox and Pharanoxi selenate were investigated experimentally. All examined antitumour agents showed embryotoxic effects. Lophenal, Phenalon and Pharanox had teratogenic effects. By modifying the structure of Pharanox with selenium a reduction in teratogenic effect was achieved.

01 Jan 1996·Journal of ChemotherapyQ4 · MEDICINE

Faranoxi-A New Antitumor Agent

Q4 · MEDICINE

Article

Author: Didziapetriene, J. ; Breivis, P.

The aim of the present study was to evaluate the antitumor activity of faranoxi experimentally and clinically. Faranoxi is a derivative of chloroethylaminophenylacetic acid containing a cytostatic group modified by oxygen in its structure. It has a broad spectrum of antitumor activity in experimental studies. One hundred eighty-eight patients with different types of malignancies were included in clinical studies. At a dosage of 90-120 mg/m2 a day for 12-15 days faranoxi is relatively well tolerated. Clinical studies demonstrate the antitumor activity of faranoxi against melanoma, lymphoma and rectal cancer. It should be noted that primary melanoma was less responsive to faranoxi compared to lymphoid metastases. Using the combination regimen FDV (faranoxi, deticene, vincristine) as treatment of melanoma, partial remission was achieved in up to 50% of the cases. Clinical trials are ongoing.

100 Deals associated with Faranoxi

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Phase 2	-	Vilnius University	-
Neoplasms	Phase 2	Lithuania	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Faranoxi

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation